Case Report

Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy

Piergiorgio Bolasco,1 Alessandra Serra,2 Maurizio Loi,3 Andrea Galfré,1 and Mario Piga2

1 Territorial Nephrology and Dialysis Department, ASL, 8 Cagliari, via Turati 4/C-Quartu Sant'Elena, Cagliari, Sardinia, Italy
2 Nuclear Medicine Department, Azienda Ospedaliero-Universitaria di Cagliari, 09124 Cagliari, Italy
3 Radiology Department, Azienda Ospedaliero-Universitaria di Cagliari, 09124 Cagliari, Italy

Correspondence should be addressed to Piergiorgio Bolasco, pg.bolasco@tin.it

Received 10 March 2010; Revised 22 April 2010; Accepted 1 June 2010

Academic Editor: Mario Maggi

Copyright © 2010 Piergiorgio Bolasco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aims of your case report is to show the predictivity of 99mTc-sestamibi (MIBI) scintigraphy and doppler ultrasound imaging on secondary hyperparathyroidism (SHPT) in a patient responsive to calcimimetic treatment. Moreover, it has been reported that calcimimetic has great potential in reducing the volume of the parathyroid gland. On the other hand, the MIBI scintigraphy is considered a crucial diagnostic procedure to monitor the response to therapy in terms of turnover and cellular metabolism; whereas, ultrasound to monitor the volume variation in response to treatment. It is described the case of a 73-year-old man on hemodialysis from 1995 for ESRD. Within 2 years the patient gradually developed SHPT with progressively increased iPTH up to 1,000 pg/ml. The ultrasound, highlighted the presence of two parathyroid hyperplasia, confirmed by scintigraphy, showing focal increase uptake of sestamibi in the same anatomical areas. As a result of the patient’s refusal to perform a parathyroidectomy, cinacalcet, was administered (65 mg overage daily dose). After a year of treatment, there was a striking decrease of iPTH (from 1300 to 57 pg/ml, −95%); but, on the contrary to expectations, this positive metabolic outcome, was not followed by parathyroid changes in ultrasound and scintigraphic findings.

1. Introduction

Over the past two years, the introduction of new drug molecules, including new phosphate binders, less-calcemic vitamin D analogues and calcimimetic, have been undergoing an incisive therapeutic change in the treatment of secondary hyperparathyroidism in haemodialysis patients. The novel vitamin D analogs, paracalcitol, doxercalciferol and others as well as calcitriol and alfacalcidol, all decrease serum PTH efficiently, but they also have a tendency to increase serum phosphorus and serum calcium [1]. Cinacalcet is a type II calcimimetic agent, that acts as an allosteric modulator of the calcium-sensing receptor, which is present on the surface of parathyroid cells, thus providing a new means of regulating PTH secretion, by amplifying the receptor’s sensitivity to extracellular calcium and reducing PTH concentrations. Cinacalcet has the same marked decrease in serum PTH as active vitamin D sterols; however, it causes a decrease of serum calcium and a minor reduction in serum phosphorus [2]. Sesta MIBI parathyroid scintigraphy is a routine imaging technique in the assessment of haemodialysis patients, not only to identify the autonomous glands requiring parathyroidectomy, but also to detect those hyperplastic parathyroids which can be suppressed by medical treatment.

A clinical case of full biochemical response to calcimetics therapy with successive regression in parathyroid volume and functionality not being present was reported.

2. Case History

A 73-year-old man, began dialysis treatment in 1995, as a result of a 10-year record of chronic kidney disease (CKD) stage II, caused by hypertensive nephroangiosclerosis. The
technique of extracorporeal therapy consisted of an endogenous hemodiafiltration (HFR) with polyethersulfone membranes, rhythm dialysis was four hours x 3/weeks dialysate: Na: 140 mmol/L, K: 2 mmol/L, bicarbonate: 30 mmol/L, and calcium: 1.5 mmol/L.

In 1997 a mild secondary hyperparathyroidism (SHPT) was detected and serum intact parathyroid hormone (iPTH) was repeatedly found at 386.5 pg/ml, (normal range 10 to 65 pg/ml, IRMA Scantibody Radim) with no associated specific symptoms. Checks by Chest X-ray, echocardiogram high-resolution computerized tomography (CT) reported an early detection of large and small vessels calcifications, including sclerodregenerative phenomena on aortic and mitral endothelium valves, despite patient dietary cooperation (there was rare evidence of hyperphosphoremia in over 10 years of dialysis also owing to a large use of sevelamer and calcium carbonate). The patient presented other comorbidities: osteoporosis and severe arthritis (former semiprofessional athlete); an early dialysis amyloidosis with consequent Baker’s cyst located in the popliteal fossa, positive for amyloid. In the same period and as a consequence of the same cause, the patient underwent bilateral neurolysis of the median nerve for carpal tunnel syndrome. No liver disease or haematologic and autoimmune diseases were present.

From 2001 to 2004 the patient started oral pulses therapy with calcitriol at dose of 1 μg three times a week without any change in iPTH levels (iPTH = 500 pg/ml). Due to a lack of response to treatment, calcitriol therapy was given intravenously at the same dose (1 μg three times/week). The iPTH showing a hyperfunctioning parathyroid gland and continued to rise and after a year it rose up to values of 1,000 pg/ml and serum alkaline phosphatase activity also increased progressively (see Table 1). Doppler ultrasonography showed two enlarged inferior parathyroid glands with hypervascularity (Figure 1), and two hot spots were detected at the same location by 99mTc-MIBI scintigraphy (Figure 2). Surgical treatment (subtotal parathyroidectomy) was proposed, but the patient repeatedly refused; therefore, we decided to initiate therapy with cinacalcet. Before beginning cinacalcet, and without changing conventional therapy (a constant dose of vitamin D and phosphate binders and receiving a stable dialysate calcium concentration), blood tests were performed to determine complete blood counts, protein electrophoresis, 25(OH)2D3, iPTH, calcium, phosphorus, ionised calcium concentration, and bone turnover markers (bone-specific alkaline phosphatase, osteocalcin). Parathyroid MIBI scintigraphy and ultrasound scanning were done at baseline, and after a year of treatment to evaluate glandular function and structure (Tables 2(a) and 2(b)). In November 2005 oral treatment with cinacalcet was initiated at a daily dose of 60 mg.

The patient continued to receive the same low dose of vitamin D sterols and phosphate binders.

During the 12 months, conventional therapy (phosphate binders, vitamin D sterol and calcium supplements) and cinacalcet was adjusted, in order to try to achieve and maintain National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) (targets for

![Figure 1](image1.png)

**Figure 1**

PTH (150–300 pg/ml), serum calcium (8.4–9.5 mg/dl), phosphorus (3.5–5.5 mg/dl), and calcium-phosphorus product (<55 mg²/dl²)). Dialysate calcium concentration and the size of the dialyzer membrane surface area were not to be changed. In a year of closed followup, serum iPTH values progressively decreased with a good control of serum phosphorus and normal serum calcium values persisted. In December 2006, after a year of treatment with cinacalcet, iPTH levels were found at 57 pg/ml with a reduction of −95% from the starting value (see Table 1).

Following neck ultrasound performance, after 12 months of cinacalcet therapy, there was the confirmation of the presence of two inferior parathyroid enlargements. The size and echographic features of these lesions remained unchanged, compared with the ultrasound images obtained before treatment. Similarly, 99mTc-MIBI parathyroid scintigraphy confirmed hyperfunctioning parathyroid tissue (Table 2(b)).
Table 1: Outcome of haematochemical and therapeutic parameters.

|                         | Start December 2005 | January–March 2006 (monthly average) | April–June 2006 (monthly average) | July–September 2006 (monthly average) | End December 2006 |
|-------------------------|---------------------|--------------------------------------|------------------------------------|---------------------------------------|-------------------|
| iPTH, pg/ml             | 1112                | 821                                  | 156                                | 125                                   | 57                |
| alkaline phosph. U/L    | 173                 | 112                                  | 142                                | 108                                   | 107               |
| bone alkaline phosph. U/L | 66.4                | 27.3                                 | 15.9                               | 12                                    | 10                |
| calcium, mg/dL          | 9.1                 | 9.3                                  | 7.8                                | 8.2                                   | 9.4               |
| phosphorus, mg/dL       | 5.6                 | 4.3                                  | 4.9                                | 4.6                                   | 4.9               |
| ionized calcium, mmol/L | 1.16                | 1.22                                 | 1.15                               | 1.14                                  | 1.22              |
| cinacalcet, average g/die | 60                  | 60                                   | 60                                 | 45                                    | 30                |
| Calcium carbonate, g/die | 2.5                 | 5                                    | 5                                  | 3.3                                   | 1.2               |
| Sevelamer, g/die        | 11.2                | 7.7                                  | 6.4                                | 6.4                                   | 4.8               |
| Calcitriol, μg/sett/os  | 0.75                | 0.75                                 | 0.75                               | 0.75                                  | 0.75              |

Table 2

(a) Scintigraphic and echographic features at the start before calcimimetic administration

**Basal study**

**99mTc-MIBI scintigraphy:**

2 parathyroid glands

Scintigraphic features

(1) Focal area of increased radiotracer uptake was present posteriorly to the lower pole of the right thyroid lobe.

(2) Another smaller area of increased radiotracer uptake was present inferiorly to the lower pole of the left thyroid lobe.

**CD ultrasound:**

2 parathyroid glands

Echographic features

(1) Nonhomogeneous hypoechoic capsulated area with a vascular pole was present posteriorly to the lower pole of the right thyroid lobe. The major three axes of the parathyroid glands were 13.8 × 10.0 × 8.0 mm.

(2) Non homogenous hypoechoic capsulated area with a vascular pole was present inferiorly to the lower pole of the left thyroid lobe. The major three axes of the parathyroid gland were 8 × 5 × 3 mm.

(b) Scintigraphic and echographic features after one year of calcimimetic administration

**After 1 year of cinacalcet therapy**

**99mTc-MIBI scintigraphy**

2 parathyroid glands

Scintigraphic features

The focal areas of increased radiotracer uptake were unmodified respect to basal control.

**CD ultrasound**

2 parathyroid glands

Echographic features

(1) Echographic structure of the lesion present posteriorly to the lower right pole of the thyroid lobe was unmodified. The major three axes of the parathyroid gland were 11 × 10 × 8 mm.

(2) Echographic lesion inferiorly to the lower pole of the left thyroid lobe was unmodified respect to basal control.

Further follow-up was not made possible due to the patient’s death of myocardial infarction three months later.

3. Discussion

Clinical evaluation of SHPT is usually carried out by the assessment of biochemical parameters and morphological and functional imaging. In recent years, various techniques including ultrasound (US), CT, magnetic resonance and MIBI-scintigraphy have been used to localize better enlarged parathyroid glands in patients with SHPT, although MIBI scintigraphy appears to be the most specific in recurrent/persistent SHPT [3–5]. Calcimimetics have become available for the treatment of dialysis patients with insufficiently controlled SHTP as well as calcium and/or phosphate.
Figure 2

levels on conventional therapies. Cinacalcet belongs to calcimimetic type II compounds that can interact with the calcium-sensing receptor CaSR, increasing its affinity to calcium. Clinical studies have proved cinacalcet to be effective in reducing calcium, phosphate, and PTH levels in hemodialysis patients with severe SHPT [6–9]. Colloton et al. [10] reported that cinacalcet inhibits the progression of parathyroid cell proliferation in rats. Meola et al. [11] described morphological ultrasound variations in hyperplastic parathyroid glands in hemodialysis patients treated with cinacalcet. They observed changes in volume, vascularisation, and sonographic patterns after 12–18 months of therapy and volume reduction was more evident in gland with basal volume <0.5 cm³. In agreement with these findings, parathyroid size regression after cinacalcet treatment has been recently reported in [12]. The literature is not yet clear if the inhibitory effect of cinacalcet on PTH secretion is associated with an effective control of parathyroid cell metabolism turnover, specially in parathyroid >0.5 cm³ [13]. In our knowledge no data has been reported about the relationship between metabolic changes and MIBI uptake in hemodialysis patients treated with calcimimetic therapy; MIBI is a lipophilic radiotracer that becomes concentrated in cells and in mitochondria through active transport and passive diffusion. The exact mechanism of its elective uptake in abnormal parathyroid glands remains debatable. The size of abnormal parathyroid does not represent the only determinant of MIBI uptake but other factors including the mitochondria numbers, degree of cellular activity, and glycoprotein P expression have been described in [14–17]. Piga et al. [18] stated that MIBI scans do not simply reveal parathyroid enlargement but rather identify hyperfunctioning parathyroid glands in patients with SHPT. Additional evidence that MIBI shows the functional status of parathyroids is found in the correlation between MIBI uptake and intact PTH in SHPT [19, 20]. Moreover, Torregrosa et al. [21] demonstrated that high MIBI uptake is correlated with the G2/S (active growth) phase.

It was shown that MIBI-scan could be used to evaluate parathyroid function as well as response to treatment with calcitriol [22, 23]. In our case with positive basal MIBI-scan after the inhibition test with calcitriol (2 μg i.v. three times/week for two weeks after haemodialysis), we could suppose two different scintigraphic findings: (1) lack of parathyroid MIBI-uptake suggestive of a reduction in metabolic activity of parathyroid glands, selecting the responders, and (2) persistence of MIBI uptake indicative of parathyroid functional autonomy, selecting the candidate patients for surgery.

In our patient the calcitriol, administered in low weekly not pulsing dose to correct hypocalcemia induced by calcimimetic, was not able to inhibit parathyroid hyperplasia. There were not detected high levels of phosphorus as a factor in stimulating hyperplasia [24]. In our case is excluded another but uncommon possibility that ultrasound and scintigraphic could be explained due to a mutation in enzyme CYP3A4 or described using other inhibitor drugs (e.g., ketoconazole, erythromycin, itraconazole) on this enzyme which could interfere in the therapeutic efficacy of calcimimetic [25]. We conclude that a ⁹⁹ᵐTc-MIBI parathyroid scan could not have showed a good correlation to the response of the cinacalcet treatment. In our case contrary to all expectactions unchanging parathyroid MIBI uptake appears seemingly to be in contrast to the inhibitory effect of calcimimetic, on parathyroid hormone secretion. Possible hypothesis to explain this paradoxical result may be the effect of cinacalcet on Ca receptors. In fact this drug increasing the membrane sensitivity to cations, as calcium, my induce a consequent increase of other cations, as MIBI, resulting in abnormal parathyroid uptake of MIBI independent of a real cellular function.

In conclusion in our case report we believe that ⁹⁹ᵐTc-MIBI scintigraphy remains to be defined as a useful method in monitoring and predicting efficacy in long-term cinacalcet therapy, in uremic patients; as well, it remains to be defined the meaning of sestamibi uptake, as an index of metabolic turnover of the parathyroid glands. Instead doppler ultrasound may represent a good marker to evaluate the regression of volume glandular. However; up until present day, there is not any clear illustration of a modification of the metabolic turnover of the parathyroid gland produced by using calcimimetic agents: surgical and histopathological confirmations should be necessary in more cases.
Conflict of Interest

No Authors declare any conflict of interest.

References

[1] S. M. Sprague and D. Coyne, “Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 3, pp. 512–518, 2010.

[2] J. Bover, A. Aguilar, J. P. Baas et al., “Calcimimetics in the chronic kidney disease-mineral and bone disorder,” International Journal of Artificial Organs, vol. 32, no. 2, pp. 108–121, 2009.

[3] D. Fuster, J. Ybarra, J. V. Torregrosa et al., “Double-phase parathyroid 99mTc-sestamibi scintigraphy in chronic haemodialysis patients: correlation with biochemical markers of parathyroid function,” Nuclear Medicine Communications, vol. 24, no. 1, pp. 85–90, 2003.

[4] M. B. Gotway, G. P. Reddy, W. R. Webb, E. T. Morita, O. H. Clark, and C. B. Higgins, “Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent or persistent hyperparathyroidism,” Radiology, vol. 218, no. 3, pp. 783–790, 2000.

[5] I. Olaizola, J. Zingriff, C. Heuguerot et al., “[(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations,” Nephrology Dialysis Transplantation, vol. 15, no. 8, pp. 1201–1206, 2000.

[6] G. A. Block, K. J. Martin, A. L. M. de Francisco et al., “Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1516–1525, 2004.

[7] M. Fukagawa, S. Yumita, T. Akizawa et al., “Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients,” Nephrology Dialysis Transplantation, vol. 23, no. 1, pp. 328–335, 2008.

[8] A. L. M. de Francisco, M. Izquierdo, J. Cunningham et al., “Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2895–2901, 2008.

[9] A. Capuano, V. Serio, A. Pota, B. Memoli, and V. E. Andreucci, “Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients,” Journal of Nephrology, vol. 22, no. 1, pp. 59–68, 2009.

[10] M. Colloton, E. Shatzen, G. Miller et al., “Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism,” Kidney International, vol. 67, no. 2, pp. 467–476, 2005.

[11] M. Meola, I. Petrucci, and G. Barsotti, “Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 982–989, 2009.

[12] H. Terawaki, H. Nakano, F. Takeguchi et al., “Regression of parathyroid gland swelling by treatment with cinacalcet,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 690–691, 2009.

[13] H. Komaba and M. Fukagawa, “Regression of parathyroid hyperplasia by calcimimetics—fact or illusion?” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 707–709, 2009.

[14] B. K. Mitchell, E. A. Cornelius, S. Zoghbi et al., “Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein,” Surgery, vol. 120, no. 6, pp. 1039–1045, 1996.

[15] S. Yamaguchi, S. Yachiku, H. Hashimoto et al., “Relation between technetium 99m-methoxyisobutylisonitrile accumulation and multidrug resistance protein in the parathyroid glands,” World Journal of Surgery, vol. 26, no. 1, pp. 29–34, 2002.

[16] F. Pons, J. V. Torregrosa, and D. Fuster, “Biological factors influencing parathyroid localization,” Nuclear Medicine Communications, vol. 24, no. 2, pp. 121–124, 2003.

[17] M. R. Custódio, F. Montenegro, A. F. P. Costa et al., “MIBI scintigraphy, indicators of cell proliferation and histology of parathyroid glands in uraemic patients,” Nephrology Dialysis Transplantation, vol. 20, no. 9, pp. 1898–1903, 2005.

[18] M. Piga, P. Baldasco, L. Satta et al., “Double-phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism,” The Journal of Nuclear Medicine, vol. 37, no. 4, pp. 565–569, 1996.

[19] D. Fuster, J. Ybarra, J. V. Torregrosa et al., “Double-phase parathyroid 99mTc-sestamibi scintigraphy in chronic haemodialysis patients: correlation with biochemical markers of parathyroid function,” Nuclear Medicine Communications, vol. 24, no. 1, pp. 85–90, 2003.

[20] G.-U. Hung, S.-J. Wang, and W.-Y. Lin, “Tc-99m MIBI parathyroid scintigraphy and intact parathyroid hormone levels in hyperparathyroidism,” Clinical Nuclear Medicine, vol. 28, no. 3, pp. 180–185, 2003.

[21] J.-V. Torregrosa, L. Fernández-Cruz, A. Canalejo et al., “(99m)Tc-sestamibi scintigraphy and intact parathyroid hormone levels in hyperparathyroidism,” Clinical Nuclear Medicine, vol. 24, no. 3, pp. 180–185, 2003.

[22] J.-V. Torregrosa, L. Fernández-Cruz, A. Canalejo et al., “(99m)Tc-sestamibi scintigraphy and intact parathyroid hormone levels in hyperparathyroidism,” Clinical Nuclear Medicine, vol. 24, no. 3, pp. 180–185, 2003.

[23] A. K. Owda, D. Mousa, A. H. Abdallah et al., “Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment,” Renal Failure, vol. 24, no. 2, pp. 165–173, 2002.

[24] J.-V. Torregrosa, D. Fuster, J. Ybarra, J. Ortín, A. Moreno, and N. Valvény, “Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy,” American Journal of Kidney Diseases, vol. 44, no. 3, pp. 476–480, 2004.

[25] E. Slatopolsky, J. Finch, M. Denda et al., “Phosphate restriction prevents parathyroid gland growth: high phosphate directly stimulates PTH secretion in vitro,” The Journal of Clinical Investigation, vol. 97, no. 11, pp. 2534–2540, 1996.

[26] D. Padhi and R. Harris, “Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride,” Clinical Pharmacokinetics, vol. 48, no. 5, pp. 303–311, 2009.